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Intimate partner violence against HIV-
positive Cameroonian women: Prevalence, 
associated factors and relationship with 
antiretroviral therapy discontinuity—results 
from the ANRS-12288 EVOLCam survey
Marion Fiorentino1,2 , Luis Sagaon-Teyssier1,2, Khadim Ndiaye1,2, 
Marie Suzan-Monti1,2, Marie-Thérèse Mengue3, Laurent Vidal1,2,  
Christopher Kuaban4, Laura March5, Christian Laurent5,  
Bruno Spire1,2  and Sylvie Boyer1,2 for the EVOLCam Study Group*
Abstract
Background: Intimate partner violence in its various forms increases HIV exposure in female victims and potentially 
jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates 
of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence 
on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-
positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence 
against HIV-positive women and its relationship with antiretroviral therapy interruption ⩾1 month.
Methods: The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The 
study sample comprised antiviral therapy–treated women declaring at least one sexual partner in the previous year. 
Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal 
component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic 
analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral 
therapy interruption ⩾1 month, and associated factors.
Results: Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% 
(physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk 
factor of antiretroviral therapy interruption ⩾1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). 
It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-
defensive violence against this partner (5.75 (3.53; 9.36)). 
Conclusion: Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability 
of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might 
help to reach the last “90” of the 90-90-90 targets.
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Introduction
Violence toward women is a worldwide public health issue 
and affects one woman in three. Perpetrators are mostly 
their intimate partners. Indeed, the latter are responsible 
for one-third of murders of women. Women physically or 
sexually abused by their partners have poorer physical, 
reproductive and mental health. Aside from mortality and 
injuries resulting from physical violence, they are also 
more likely to experience depression, to acquire sexually 
transmitted diseases and to have induced abortions or 
babies with low birth weight.1,2 Intimate partner violence 
(IPV) also has an intergenerational effect on IPV itself3 
and on poor health outcomes.
IPV increases the risk of HIV acquisition, may delay or 
prevent HIV testing and HIV status disclosure to partners4,5 
and exacerbates the vulnerability of women living with HIV 
(WLHIV). WLHIV are at greater risk for domestic and fam-
ily exclusion than other women.4 IPV among people living 
with HIV (PLHIV) is associated with decreased access or 
use of healthcare services,6–9 poorer engagement in HIV 
care, sub-optimal antiviral therapy (ART) adherence10,11 and 
lower health-related quality of life, which is a strong predic-
tor of death in PLHIV.11,12 Suicidal ideation and attempts, 
depression, anxiety or post-traumatic disorders are more 
frequent in HIV-positive persons suffering from IPV than in 
other PLHIV, all of which affect ART adherence, immune 
functions and viral suppression.12,13 To summarize, IPV is 
greatly interconnected with HIV and health outcomes of 
PLHIV and may jeopardize the implementation and success 
of various elements of the HIV treatment cascade.
IPV and HIV are both endemic in Central Africa.4,14 In 
2014, Cameroon was the 15th country most affected by 
HIV worldwide. Only 37% of PLHIV there received ART 
and only 19% were virally suppressed.14 The lack of real 
progress toward achieving the UNAIDS 90-90-90 targets is 
a concern for the control of the epidemic in the country. In 
2016, of the 32,000 new HIV infections, 4000 were due to 
mother-to-child transmission.14 The 330,000 WLHIV in 
Cameroon account for 65% of all PLHIV in the country, a 
prevalence of 5.1% in women compared with 2.5% in men. 
In addition, Cameroon has the fifth highest prevalence of 
IPV among Sub-Saharan African countries. According to 
the 2011 Demographic Health Survey, nearly half of all 
Cameroonian women had recently suffered emotional, 
physical and/or sexual IPV.15 In this setting, where the 
prevalence of both HIV infection and IPV is particularly 
high, no study has yet investigated the relationship between 
IPV and ART discontinuity in women. Antiretroviral ther-
apy interruption (ATI) compromises the control of the HIV 
epidemic16 and is a stronger risk factor than sub-optimal 
ART adherence for virological failure and HIV drug resist-
ance17,18 which are both very prevalent in Cameroon.19
The ANRS-12288 EVOLCam cross-sectional survey 
was conducted in 2014 in Cameroon to study the living 
conditions of PLWH followed up in 19 HIV services in the 
Center and Littoral regions, established as part of the 
national ART program. A previously published analysis 
from that survey reported that 21% of PLWH reported 
ATI.20 The two objectives of this study were first to inves-
tigate whether IPV was associated with ATI among 
WLHIV participating in this survey and second to describe 
the prevalence of the different forms of IPV in this sub-
population and identify associated risk factors.
Methods
Study design, participants and data collection
The ANRS-12288 EVOLCam study was a cross-sectional 
survey conducted in the Center and Littoral regions of 
Cameroon between April and December 2014 which 
recruited 2357 eligible PLHIV (⩾21 years old, HIV-
diagnosed >3 months) attending one of the study’s 19 par-
ticipating HIV services. Details about recruitment can be 
found elsewhere.20 Demographic, socioeconomic, domes-
tic and psychosocial data were collected during face-to-
face interviews performed by independent, trained 
interviewers. The questionnaire included a section dealing 
with IPV previously developed by the World Health 
Organization (WHO) for a multi-country study on wom-
en’s health and domestic violence against women.21 
Participating women were asked 12 behavior-specific 
questions about acts of violence (physical and mental) they 
might have had suffered from their most recent intimate 
partner in the 12 months prior to the survey and the fre-
quency of these acts (never occurred, occurred occasion-
ally or occurred frequently). Clinical data were obtained 
from medical files. A blood sample was collected from 
patients treated >6 months to measure HIV viral load 
(VL) and was analyzed by a reference HIV laboratory in 
Yaounde accredited by the WHO (quantification threshold 
100 copies/mL). All participants provided written informed 
consent. ANRS-12288 EVOLCam was approved by the 
Ministry of Public Health in Cameroon and the 
Cameroonian National Ethics Committee. The study pop-
ulation of the present analysis included women declaring 
at least one intimate partner in the 12 months prior to the 
survey and having no missing data in the IPV section of 
the questionnaire.
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IPV scores
We performed a principal component analysis (PCA) on 
the 12 items of the IPV questionnaire section to build IPV 
scores which, by construction, were standardized and 
computed using values ranging from 0 (no violence) to 1 
(high level of violence). The Promax rotation technique, 
which enables correlation between factors, was imple-
mented to improve the fit of the data.22 IPV was broken 
down into four factors allowing the construction of the fol-
lowing scores (Appendix 1): emotional IPV (based on 
three items, eigenvalue = 2.55, Cronbach’s α = 0.871), 
physical IPV (five items, eigenvalue = 3.72, Cronbach’s 
α = 0.929), extreme physical IPV (two items, eigen-
value = 1.67, Cronbach’s α = 0.685) and sexual IPV (two 
items, eigenvalue = 1.62, Cronbach’s α = 0.582). The pre-
vious scores were considered highly reliable when 
Cronbach’s α value was ⩾0.7 and moderately reliable 
when the value was [0.5; 0.7[.23,24 The IPV scores explained 
cumulatively 80% of the total variance. A three-class IPV 
variable (no, occasional and frequent violence) was built 
using the following IPV score cut-offs: score = 0 (no IPV), 
score <median among non-zero values (occasional IPV) 
and score ⩾median among non-zero values (frequent 
IPV).
Outcomes
ATI was an intermediary outcome in order to verify 
whether it was associated with one or more IPV scores. 
ATI ⩾1 month (ATI ⩾ 1m) was classified into three types: 
recent, that is, ATI ⩾ 1m in the 6 months prior to the sur-
vey; former, that is, ATI ⩾ 1m older than 6 months; and 
none, that is, no ATI > 1m since the beginning of ART.
IPV scores were defined as binary variables (frequent 
vs occasional or none). Those associated with recent 
ATI ⩾ 1m were then used as the main outcomes of this 
study in order to investigate related factors.
Explanatory variables
The following variables were common to both the interme-
diary and main analyses: age (in four categories defined 
using quartiles), living setting (rural, urban), educational 
level (primary, secondary, post-secondary), professionally 
active (yes, no), monthly household income (in four cate-
gories defined using quartiles), having children (yes, no), 
relationship with the household head (being the household 
head, spouse or ascending line, descending line or other 
family relationship or no family relationship), having a 
main partner (yes, no), experiencing ART stock-outs in the 
previous 3 months (yes, no), HIV clinical stage at ART ini-
tiation (stages 1–4).25
In addition, the following factors were used in the anal-
ysis investigating factors associated with ATI-related IPV: 
duration of relationship with the main partner (in four cat-
egories defined using quartiles), living together (living 
with the main partner, not living together, no main part-
ner), marital status (legal or customary marriage, common-
law couple, no main partner), kind of union (polygamous, 
monogamous, no main partner), educational level of the 
main partner (primary, secondary, post-secondary, 
unknown, no main partner), decision making about how to 
spend the respondent’s income (the main partner alone, 
other responses), decision making about the respondent’s 
health care (the main partner alone, other responses), HIV 
status disclosure to the most recent intimate partner (yes, 
no), HIV status of the most recent intimate partner (posi-
tive, negative, unknown), age difference between the 
respondent and her most recent intimate partner (>5 years, 
⩽5 years, unknown), having perpetrated non-self-defen-
sive violence against her intimate partner (yes, no) and 
having experienced stigma (stigma score >0, stigma 
score = 0 as measured by the HIV Stigma Scale).26
Statistical analysis
Relationship between IPV and ATI ⩾ 1m. Univariate logistic 
regressions were performed to evaluate the relationships 
between ATI ⩾ 1m and (a) the binary variables of emo-
tional, physical, extreme physical and sexual IPV; (b) all 
the previously listed possible explanatory variables.
Multivariate logistic regression was performed includ-
ing the binary variables of emotional, physical, extreme 
physical and sexual IPV, age and variables with a p value 
of <0.2 in the univariate analysis. Causal mediational 
analysis was further performed to investigate the influence 
of mental and physical quality of life (scores calculated by 
using the SF-12 scale)27 on the association between recent 
ATI ⩾ 1m and IPV.
Factors associated with ATI-related IPV. Univariate logistic 
regression was then performed to investigate the associa-
tions of IPV scores previously identified as related to 
recent ATI ⩾ 1m and the previously cited explanatory vari-
ables. Multivariate logistic regression was performed 
including variables with a p value of <0.2 in the univariate 
analysis, using the backward stepwise technique. All the 
statistical analyses were performed using R 3.5.0.28
Results
Characteristics of participants
Of the 2138 participants in the ANRS-12288 EVOLCam 
survey, 1387 (65%) were female. Among them, 934 
women declared at least one intimate partner in the previ-
ous 12 months. Of the latter, 894 (64% of all women 
included in the survey) had no missing values in the IPV 
questionnaire section and were therefore included in this 
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Table 1. Characteristics of HIV-positive ART-treated 
Cameroonian women who declared at least one intimate 
partner in the previous 12 monthsa (ANRS-122988 EVOLCam 
survey, n = 894).
N (%) or median (IQR)
Demographic and socioeconomic characteristics
Age (years) 37 (32–42)
Residential setting
 Urban area 79.9%
 Rural area 15.3%
Educational level
 Primary level 33.1%
  Secondary and post-secondary level 66.9%
Professionally active
 No 37.4%
 Yes 62.6%
Monthly household income per 
consumption unit (FCFA) (USD)
8095 (4167–14,535)
14.9 (7.7–26.8)
Psychosocial characteristics
HIV-related stigma
 Experienced 26.2%
 Not experienced 73.8%
Physical quality of life (index) 51.9 (42.2–55.5)
Mental quality of life (index) 44.5 (38.1–51.7)
Alcohol consumptionb
 No consumption 42.1%
 Moderate consumption 54.5%
 Elevated consumption 2.6%
Number of intimate partners in the previous 12 months
 1 86.2%
 ⩾2 13.8%
Domestic characteristics
Number of children
 None 13.5%
 1 child 21.9%
 ⩾2 children 64.2%
Relationship with the household head
 Herself 38.7%
 Spouse/partner or ascending line 44.2%
  Descending line, or other/no 
family relationship
17.1%
Having a main partner
 Yes 84.3%
 No 15.7%
Duration of relationship with main 
partner (years)
5 (2–12)
Living together with the main partner
 No 36.5%
 Yes 46.5%
Type of union
 Monogamous union 69.1%
 Polygamous union 13.3%
Educational level of main partner
 ⩽Primary level 14.8%
  Secondary level or post-
secondary level
67.2%
N (%) or median (IQR)
 Unknown 16.1%
The main partner of the respondent alone makes decisions 
about
 How to spend the respondent’s 
income
5.8%
 The respondent’s health care 11.7%
Characteristics of the most recent intimate partnerc
Type of partner at the most recent sexual encounter
 Main partner 94.4%
 Occasional partner 5.4%
HIV status disclosure to the most recent intimate partner
 No 27.5%
 Yes 70.2%
HIV status of the most recent intimate partner
 Negative 37.1%
 Positive 23.6%
 Unknown 38.7%
Age difference between respondent and most recent intimate 
partner
 ⩽5 years 21.9%
 >5 years 76.8%
 Unknown 0.9%
Clinical characteristics
ATI ⩾1 month since ART initiationd
 No 86.9%
 Yes, recent ATI 5.1%
 Yes, former ATI 8.0%
Viral load (VL)e
 Undetectable 71.6%
 Detectable 28.4%
Experiencing ART stock-out(s) in the previous 3 months
 Yes 16.3%
 No 75.0%
ART: antiviral therapy; ATI: antiretroviral therapy interruption; IQR: 
interquartile range; IPV: intimate partner violence.
aWith no missing data in the IPV questionnaire.
bAlcohol consumption: moderate, ⩽3 big or 6 small bottles of 
beer (i.e. ⩽195 cL); elevated, ⩾4 big or 7 small bottles of beer (i.e. 
⩾230 cL).
cIn the 12 +months prior to the survey.
dATI ⩾ 1 month: recent, ATI ⩾ 1m = in the 6 months prior to the survey 
and former, ATI ⩾ 1m = more than 6 months prior to the survey.
eData on women with ART ⩾6 months (n = 852); undetectable VL 
⩽100 copies/mL.
(Continued)
Table 1. (Continued)
study. Median (interquartile range (IQR)) age was 37 (32–
42) years (Table 1). A large proportion of women were liv-
ing in urban areas (80%), were professionally active 
(63%), and had a secondary educational level (60%). 
Seventy three percent of participants had experienced 
HIV-related stigma. Sixteen percent of those included 
experienced ART stock-out(s) in the 3 months prior to the 
survey and 28% percent had a detectable VL.
A large proportion of women had disclosed their HIV 
status to their most recent intimate partner (70%), but 39% 
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did not know this partner’s HIV status, while 37% and 
24%, respectively, declared that their most recent intimate 
partner was HIV-negative and HIV-positive.
Description of IPV
The proportions of women reporting occasional or fre-
quent IPV was 29% for emotional IPV, 22% for physical 
IPV, 13% for extreme physical IPV and 18% for sexual 
IPV (Table 2). Median scores of emotional IPV, physi-
cal IPV, extreme physical IPV and sexual IPV were, 
respectively, 0.297, 0.288, 0.013 and 0.026 among 
women who declared IPV. Thirteen percent of partici-
pants declared they had perpetrated non-self-defensive 
physical violence against their most recent intimate 
partner.
Association of IPV with recent ATI ⩾1m
For this study, we focused only on IPV association with 
recent ATI ⩾ 1m, due to the cross-sectional design of the 
survey. Accordingly, results for previous ATI ⩾ 1m are not 
shown. The analysis of IPV association with ATI ⩾ 1m 
was performed on 815 of the 894 WLHIV included in this 
study, as 5 had missing data on treatment interruption and 
74 women were not receiving ART at the time of the study. 
In the final model, the risk of recent ATI ⩾ 1m was higher 
in women suffering from frequent physical IPV than in 
those reporting no or occasional IPV (Table 3; adjusted 
odds ratio (aOR) = 2.42 (95% confidence interval 
(CI) = 1.00; 5.87), p = 0.051). Recent ATI ⩾ 1m was 
reported, by 8%, 6% and 5% of women who reported, 
respectively, frequent, occasional or no physical violence. 
Other IPV scores were not associated with recent ATI ⩾ 1m. 
The other factors also independently associated with recent 
ATI ⩾ 1m as follows: experience of ART stock-outs in the 
previous 3 months (2.14 (1.04; 4.41), p = 0.039), women 
aged 32–37 years (0.19 (0.04; 0.87), p = 0.032), monthly 
household income per consumption unit >75th percentile, 
that is, ⩾US$26.8 (4.67 (1.64; 13.29) p = 0.004) and ]50th–
75th] percentile, that is, ]US$14.9–US$26.8] (2.77 (0.95; 
8.15), p = 0.063). In the causal mediational analysis, no 
mediation effect of mental and physical quality of life 
scores was found in the association between frequent 
physical IPV and recent ATI ⩾ 1m (average causal media-
tion effects: mental life quality index, coeffi-
cient = –0.00175, p = 0.616; physical life quality index, 
coefficient = –0.000581, p = 0.870; data not shown).
Factors associated with frequent physical IPV
Eight hundred and nighty-four women were included in 
the analysis of factors associated with frequent physical 
IPV. In multivariate analysis (Table 4), women living with 
their main partner (2.03 (1.20; 3.44), p = 0.009), those who 
experienced HIV-related stigma (2.53 (1.58; 4.02), 
p < 0.001) and those who reported non-self-defensive vio-
lence against their most recent intimate partner (5.75 (3.53; 
9.36), p < 0.001) were all significantly more likely to 
experience frequent physical IPV.
Discussion
High IPV prevalence in Cameroonian WLHIV
IPV is an important concern in HIV-positive women in 
Cameroon, with one-third of our participants suffering emo-
tional IPV, one-fifth suffering sexual and/or physical IPV, and 
one-eighth suffering extreme physical IPV. These findings are 
consistent with results which reported higher exposure to IPV 
in PLWH than in other related  HIV-negative sub-populations, 
in Sub-Saharan Africa,29,65  and in various settings.5 However, 
the prevalence of IPV, especially sexual and emotional IPV, 
Table 2. Description of intimate partner violence in HIV-
positive ART-treated Cameroonian women who declared at 
least one intimate partner in the previous 12 monthsa (ANRS-
122988 EVOLCam survey, n = 894).
N (%) Median IPV score (IQR)b
Emotional IPV 0.297 (0.141–0.372)
 Presentc 261(29.2%°)  
  Occasionald 122 (13.7%)  
  Frequente 139 (15.5%)  
 Absentf 633 (70.8%)  
Physical IPV 0.288 (0.062–0.462)
 Presentc 193 (21.6%)  
  Occasionald 96 (10.7%)  
  Frequente 97 (10.9%)  
 Absentf 701 (78.4%)  
Extreme physical IPV 0.013 (0.007–0.047)
 Presentc 115 (12.9%)  
  Occasionald 57 (6.4%)  
  Frequente 58 (6.5%)  
 Absentf 779 (87.1%)  
Sexual IPV 0.026 (0.007–0.152)
 Presentc 163 (18.3%)  
  Occasionald 81 (9.1%)  
  Frequente 82 (9.2%)  
 Absentf 731 (81.7%)  
Non-self-defensive violence perpetrated against most recent 
intimate partnerg
 No 777 (86.9%)  
 Yes 113 (12.6%)  
ART: antiviral therapy; IPV: intimate partner violence; IQR: interquar-
tile range.
aWith no missing data in the IPV questionnaire.
bMedian score and IQR calculated for all non-zero scores.
cIPV score >0.
dIPV score < median IPV scoreb.
eIPV score ⩾median IPV scoreb.
fIPV score equal to zero.
g“Have you ever beaten up, slapped, hit, kicked or physically assaulted 
your (most recent) intimate partner when he was not assaulting you?”
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observed in this study, was particularly high compared with 
other research conducted among WLHIV in Sub-Saharan 
Africa.29–31 The higher prevalence of recent IPV might reflect 
the higher prevalence of IPV in the Cameroonian general 
population than in other countries.14
In our study population, the prevalence of emotional 
IPV was similar to that of women in the general population 
of Cameroon. However, sexual IPV was higher and physi-
cal IPV was lower, as indicated by the 2010 demographic 
and health national survey (respectively, 29%, 22% and 
18% in the general population vs 33%, 29% and 11% in our 
study population (15)). The higher exposure of HIV-
positive women to sexual IPV than in the general popula-
tion of women in Cameroonian might partly explain their 
HIV acquisition. Indeed, there is growing evidence that 
IPV, especially sexual IPV, increases HIV exposure and 
incidence in women.4,32–35 Moreover, abusive partners are 
more likely to have HIV risky behaviors and sexually trans-
mitted infections (STIs) than non-violent partners, which 
increases women’s risk of exposure to HIV.1 However, it is 
also possible that HIV diagnosis and status disclosure to 
their intimate partner in our population may have increased 
their exposure to physical violence.4,12 In this study, two-
thirds of women had disclosed their HIV status to their 
most recent intimate partner, which was their main partner 
in most cases. However, no statistical association was 
found between serodisclosure and frequent physical IPV, 
perhaps because IPV might occur as a result of disclosure,6 
or indeed prevent disclosure,36 due to a fear of violence.
IPV and ATI
This study highlights an association between frequent 
physical IPV and prolonged ATI. One study among 
Table 3. Factors associated with recent ATI ⩾1 montha in ART-treated HIV-positive Cameroonian women (ANRS-122988 
EVOLCam survey, n = 815b).
Univariate analysisc Multivariate analysisd
 OR (95% CI) p aOR (95% CI) p
Age (ref.: ⩽32 yearse)
 ]32; 37] yearsf 0.19 (0.04; 0.87) 0.033 0.19 (0.04; 0.87) 0.032
 ]37; 42] yearsg 1.24 (0.56; 2.72) 0.596  
 >42 yearsh 1.28 (0.57; 2.88) 0.554  
Socioeconomic characteristics
Monthly household income (ref.: <7.7 USD/cue)
 ]7.7–14.9] USD/cuf 1.80 (0.58; 5.62) 0.311  
 ]14.9–26.8] USD/cug 2.45 (0.85; 7.11) 0.099 2.77 (0.95; 8.15) 0.063
 ⩾26.8 USD/cuh 3.87 (1.40; 10.74) 0.009 4.67 (1.64; 13.29) 0.004
Domestic characteristics
Relationship with the household head (ref. being the household head)
 Spouse or ascending line 0.54 (0.26; 1.13) 0.103  
 Descending line, other/no family relationship 1.47 (0.68; 3.19) 0.334  
Having a main partner (ref. no) 2.39 (0.73; 7.89) 0.152  
Intimate partner violence
Frequenti emotional IPV (ref. absentj or occasionalk) 0.91 (0.37; 2.21) 0.828  
Frequenti physical IPV (ref. absentj or occasionalk) 1.95 (0.83; 4.56) 0.125 2.42 (1.00; 5.87) 0.051
Frequenti extreme physical IPV (ref. absentj or occasionalk) 1.32 (0.39; 4.47) 0.656  
Frequenti sexual IPV (ref. absentj or occasionalk) 0.5 (0.12; 2.14) 0.351  
Living with HIV
Experiencing ART stock-outs in the previous 3 months (ref. no) 2.11 (1.05; 4.25) 0.037 2.14 (1.04; 4.41) 0.039
ART: antiviral therapy; ATI: antiretroviral therapy interruption; CI: confidence interval; cu: consumption unit; OR: odds-ratio; aOR: adjusted odds 
ratio; IPV: intimate partner violence
aRecent ATI ⩾ 1 month = ATI ⩾ 1 month in the 6 months prior the survey
bDue to five missing values on ATI ⩾1 month and 74 women not receiving ART
cExcept IPV variables, only associations with p value of <0.2 are presented (variables included in the multivariate analysis)
dOnly associations with p value of <0.1 are presented
e<25th percentile
f]25th–50th] percentile
g]50th–75th] percentile percentile’ is correct as given in the footnote of Table 3.]
h⩾75th percentile
iFrequent IPV score above median score (calculated for all non-zero scores)
jFrequent IPV score equal to zero
kFrequent IPV score below median score (calculated for all non-zero scores)
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American WLHIV showed more frequent prolonged 
healthcare interruptions leading to viral rebound among 
victims of IPV.37 Unstructured prolonged ATI has been 
found to compromise immunological recovery and viral 
suppression and increase comorbidity, mortality and resist-
ance to antiretroviral treatment.38–40 Increased VL in 
Table 4. Factors associated with frequent physical IPVa experience in HIV-positive Cameroonian women (ANRS-122988 
EVOLCam survey, n = 894).
Univariate analysisb Multivariate analysisc
 OR (95% CI) p aOR (95% CI) p
Sociodemographic characteristics
Living in a rural area (ref. urban) 1.57 (0.92; 2.68) 0.097  
Age (ref.: ⩽32 yearsd)
 ]32; 37] yearse 0.85 (0.49; 1.49) 0.580  
 ]37; 42] yearsf 0.62 (0.35; 1.10) 0.101  
 >42 yearsg 0.64 (0.35; 1.17) 0.144  
Domestic characteristics
Relationship with the household head (ref. being the household head)
 Spouse or ascending line 1.42 (0.88; 2.31) 0.152  
 Descending line, other/no family relationship 1.58 (0.87; 2.89) 0.134  
Duration of couple relationship (ref.: <3 years)
 [3–7[ yearse 0.58 (0.28; 1.22) 0.152  
 [7–14[ yearsf 1.29 (0.56; 2.95) 0.545  
 ⩾14 yearsg 0.93 (0.42; 2.06) 0.861  
 Did not have a main partner 0.84 (0.38; 1.90) 0.682  
Living together (ref. not living together)
 Living together with main partner 2.00 (1.21; 3.30) 0.007 2.03 (1.20; 3.44) 0.009
 Did not have a main partner 1.62 (0.83; 3.16) 0.154 1.42 (0.70; 2.88) 0.332
Educational level of main partner (ref. ⩽primary level)
 Secondary level 0.73 (0.40; 1.31) 0.290  
 Post-secondary level 0.80 (0.40; 1.59) 0.524  
 Unknown 0.25 (0.10; 0.62) 0.003  
 Did not have a main partner 0.72 (0.36; 1.46) 0.367  
The main partner alone makes all the decisions about how to 
spend the respondent’s income (ref. other decision-makerh)
1.78 (0.84; 3.77) 0.133  
Characteristics of the most recent intimate partneri
Age difference between respondent and the most recent intimate partner (ref.: ⩽5 years)
 >5 years 1.48 (0.85; 2.60) 0.170  
 Unknown 1.61 (0.19; 13.89) 0.666  
Non-self-defensive violence perpetrated against the most 
recent intimate partnerj (ref. no violence)
6.28 (3.91; 10.08) <0.001 5.75 (3.53; 9.36) <0.001
Psychosocial characteristics
Stigma (ref. no stigma) 2.41 (1.56; 3.71) <0.001 2.53 (1.58; 4.02) <0.001
Alcohol consumption (ref. no consumption)k
 Moderate consumption 1.56 (0.99; 2.47) 0.055  
 Elevated consumption 1.67 (0.47; 5.93) 0.428  
CI: confidence interval; OR: odds-ratio; aOR: adjusted odds ratio; IPV: intimate partner violence.
aIPV score above median score (calculated for all non-zero scores), reference: no physical IPV (IPV score equal to zero) or occasional physical IPV 
(IPV score below median score).
bOnly associations with p value of <0.2 are presented (variables included in the multivariate analysis).
cOnly associations with p value of <0.1 are presented.
d<25th percentile.
e[25th–50th] percentile.
f[50th–75th] percentile.
g⩾75th percentile.
hThe respondent herself, the respondent together with her main partner, someone else or someone else together with the respondent.
iIn the 12 months prior to the survey.
j“Have you ever beaten up, slapped, hit, kicked or physically assaulted your most recent intimate partner when he was not assaulting you?”
kAlcohol consumption: moderate ⩽3 big or 6 small bottles of beer (i.e. ⩽195 cL) and elevated ⩾4 big or 7 small bottles of beer (i.e. ⩾260 cL), when 
the respondent drinks alcohol.
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HIV-positive people who interrupt their ART is a major 
predictor of the risk of vertical41 and horizontal transmis-
sion of HIV.42 Because women who are victims of IPV are 
more likely to interrupt ART for a long period, both their 
new-born children and HIV-negative intimate partners are 
at greater risk of HIV infection, as are their abusive part-
ners’ concurrent partners. IPV jeopardizes HIV control at 
both the individual and collective levels.
Furthermore, the experience of emotional, physical or 
sexual violence is associated with poor psychosocial out-
comes in HIV-positive women,37,43 which are known to be 
predictors for sub-optimal ART continuity or adherence.44 
Therefore, the effect of violence on linkage to and reten-
tion in health care is either direct, because of freedom dep-
rivation, or indirect, by degrading the quality of life or 
mental health,45 which in turn affects healthcare use. 
However, in this study, quality of life was shown to have 
no mediation effect on the association between frequent 
physical IPV and recent ATI ⩾ 1m. As suggested in a pre-
vious national survey conducted in Cameroon, ATI is more 
related to exogenous events than to individual decisions.46 
Therefore, in this specific setting, violent partners might 
directly affect women’s use of health care by controlling 
them or by limiting how much money they have and how 
they use it, or by limiting their use of transportation rather 
than by degrading their mental quality of life.
Factors associated with physical IPV among 
Cameroonian WLVIH
Stigma was associated with frequent physical IPV in HIV-
positive women in this study. Women who suffer HIV-
related stigma are more likely to be socially isolated and 
helpless toward their partners’ violence. Non-defensive 
violence perpetrated by the women on their partners, as 
well as cohabitation with their partners, were identified as 
risk factors for frequent physical IPV in this study, which 
is consistent with findings of a multi-country study con-
ducted by the WHO.47 Qualitative research investigated 
how cohabitation with partners is linked to IPV and poor-
related health outcomes among HIV-positive women, 
through sexual slavery, confinement and healthcare access 
control and dissuasion.45 Aside from these factors, no edu-
cational or socioeconomic characteristic of the women or 
their partners was associated with recent physical IPV in 
this study, which is consistent with observations made in 
the general population in Cameroon.15
Further research in Cameroon should investigate the 
health effect of domestic violence in HIV-positive women 
and men in greater detail. Domestic violence is not limited 
to violence perpetrated on women by their partners, but 
includes emotional and physical violence inflicted by co-
wives in polygamous unions (which accounted for 13% of 
our study sample), or by in-laws.48 Violence perpetrated by 
women on their partners, reported by 13% of our study 
sample, is related to violence they suffer and may also 
have an adverse impact on their male partner’s health and 
HIV-related outcomes.48
Addressing IPV in HIV-positive women
When we consider the large proportion of women who are 
victims of IPV, the absence of demographic or socioeco-
nomic criteria to identify those at risk of IPV, and the fact 
that in Cameroon, most physical and sexual IPV starts in 
the early years of a relationship,15,16 we see that a major 
proportion of women followed up in HIV services are at 
risk of IPV. This fact justifies the need for systematic 
screening for IPV in these patients.
The most promising interventions to concomitantly 
address HIV and IPV in low-income countries are those 
which combine economic strengthening and gender-trans-
formative interventions49 and involve men.50 However, 
these are mostly designed to prevent HIV acquisition by 
women in contexts where IPV is widespread51–53 as 
opposed to help women already infected. Data on inter-
ventions to reduce IPV endured by HIV-positive African 
women and related poor outcomes are scarce. Skills and 
practices of workers in HIV services, as well as their regu-
lar contact and lifelong relationship with patients should 
be used to address IPV-related effects. Peers strongly rec-
ommend integrating universal screening for IPV in 
mother-to-child HIV transmission prevention programs, 
and in outreach for testing and ART programs, in order to 
achieve viral suppression in WLHIV.54 IPV appears to be 
less spontaneously discussed by women in health services 
than other intimate issues such as condom and contracep-
tive use.31 This suggests that healthcare providers need to 
raise the IPV subject instead of waiting for their patient to 
do so, and to screen for IPV by searching for identifying 
features (e.g. wounds and traces of punches).12 A previous 
study investigated how acceptable it was to women to be 
asked about their experiences of IPV in counseling and 
testing services.55 A few interventions to facilitate safe 
HIV serostatus disclosure options and sex negotiation in 
HIV-positive women who experience or fear IPV have 
been implemented, but with limited evidence for their 
success.56
Consequently, we recommend implementing universal 
counseling and screening for IPV (endured or mutual) and 
other forms of domestic violence, in both male and female 
patients, in healthcare services dedicated to testing, post-
testing and ART provision, in accordance with the guide-
lines from the WHO 2006 report57 and 2013 programming 
tool.58 We also recommend that same-gender counselors 
be used where possible.59 Implementing and evaluating the 
efficiency of such healthcare provider-led care interven-
tions to improve ART continuity, viral suppression, HIV 
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transmission and other health outcomes in the context of 
IPV is a currently unexplored opportunity for research.60
Strengths and limitations of the study
The study did not include women attending HIV services 
in areas other than Center and Littoral regions, and more 
importantly, it did not include HIV-positive women not 
attending HIV services, a sub-population believed to be at 
greater vulnerability. Accordingly, our results are not rep-
resentative of the overall situation of WLHIV in Cameroon. 
However, the study is representative of HIV-positive 
women receiving ART within the Cameroonian ART pro-
gram in the two regions cited. Furthermore, the study’s 
cross-sectional design did not allow us to establish causal 
mechanisms. In addition, our study relied on self-reported 
IPV, which is a sensitive issue, possibly inducing declara-
tive bias. However, the WHO questionnaire used to collect 
IPV data has been validated and is considered highly reli-
able in discriminating different forms of violence in differ-
ent social contexts.59 PCA has already been used by other 
researchers to construct scores of IPV using a large num-
ber of items reporting IPV in face-to-face questionnaires.60 
To our knowledge, this is the first study to investigate IPV 
suffered by ART-treated HIV-positive Cameroonian 
women and its associated factors, as well as the associa-
tion between IPV and prolonged ATIs among HIV-positive 
women in Cameroon.
Conclusion
The high proportion of women attending HIV services in 
the Center and Littoral regions of Cameroon who suffer 
from various forms of IPV is a great cause for concern. 
While sexual IPV may have contributed to their HIV 
acquisition, physical IPV increases the risk of prolonged 
ATIs, which may degrade health outcomes, increase vul-
nerability and negatively affect both the control of HIV 
and the HIV treatment cascade. In the context of the inter-
connection between the IPV and HIV epidemics in 
Cameroon, screening for IPV and providing counseling in 
HIV services offer the opportunity to identify patients at 
risk of poor health outcomes and to mitigate the effects of 
IPV not only on themselves but on their partners, their 
children and on public health. Combined with measures to 
address supply-related barriers to ART continuity, identi-
fied in the ANRS-12288 EVOLCam survey,20 these efforts 
could both consolidate the important progress which 
Cameroon has already made in engagement in HIV care 
since the adoption in 2007 of a national policy of free 
access to ART63,64 and improve the treatment cascade.
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Appendix 1. Frequency of IPV items and detailed results of principal components analysis used to construct IPV scores from IPV 
items.
IPV items IPV indicators
In the past 12 months, has your most 
recent partner ever …
Never Sometimes Often Emotional 
IPV score
Physical IPV 
score
Extreme physical 
IPV score
Sexual IPV 
score
n % n % n % Ranking of IPV items in constructing IPV indicators 
according to weighting from PCA
said or done something to humiliate 
you in front of other people?
752 84.1 80 8.9 62 6.9 0.92 0.02 −0.02 −0.03
insulted or belittled you? 718 80.3 102 11.4 74 8.3 0.90 0.04 −0.05 −0.05
threatened to hurt you or someone 
you care about?
773 86.5 64 7.2 57 6.4 0.84 −0.04 0.12 0.06
hit you with his fist or with 
something else that could hurt you?
820 91.7 45 5 29 3.2 −0.03 0.93 0.04 −0.08
twisted your arm or pulled your 
hair?
820 91.7 40 4.5 34 3.8 −0.09 0.93 −0.05 0.18
slapped you? 770 86.1 77 8.6 47 5.3 0.14 0.86 −0.13 0.01
kicked you, dragged you or beaten 
you up?
834 93.3 34 3.8 26 2.9 −0.07 0.86 0.22 −0.16
pushed you or shoved you or 
thrown something at you?
790 88.4 60 6.7 44 4.9 0.18 0.74 −0.07 0.14
threatened to use or did in fact 
use a gun, knife, or other weapon 
against you?
883 98.8 5 0.6 6 0.7 0.02 −0.14 0.93 0.13
tried to or did in fact choke you or 
burn you on purpose?
869 97.2 10 1.1 15 1.7 0.02 0.24 0.75 −0.09
physically forced you to have sexual 
intercourse even when you did not 
want to?
838 93.7 32 3.6 24 2.7 0.07 0.03 0.09 0.74
forced you to practice any other 
sexual act that you did not want to?
877 98.1 8 0.9 9 1 −0.07 0.01 0 0.92
 Eigen values 2.55 3.72 1.67 1.62
 Explained 
variance
21.3% 31.0% 13.9% 13.5%
 Cumulative variance 79.6%
 Cronbach’s α 0.871 0.929 0.685 0.582
 Correlation with other IPV score  
 Emotional IPV score − 0.610 0.382 0.396
 Physical IPV score − − 0.540 0.360
 Extreme physical IPV score − − − 0.286
IPV: intimate partner violence; PCA: principal component analysis.
Bold values indicate that the IPV item highly contributes to the construction of the IPV score (weighting >0.7)
